May 31- Valeant Pharmaceuticals Inc, which has come under scrutiny for its business and accounting practices, said on Tuesday it would host a conference call on June 7 to discuss first-quarter results. The Beleaguered Canadian drugmaker reiterated that it expects to file its quarterly report with U.S. and Canadian regulators on or before June 10, ahead of a July... » Read More
Stocks opened lower Friday as crude oil dropped below $71 a barrel and banks dragged after Bank of America lowered its outlook for the sector.
Futures pointed to a negative open for Wall Street Friday as crude oil dropped below $71 a barrel and banks dragged after Bank of America lowered its outlook for the sector.
To almost no one's surprise, for the first time in 41 years, the World Health Organization has declared a full-blown swine flu pandemic. But the declaration is tied more to the geographic spread of the virus than it is to its virulence.
Dr. Mark Monane, senior biotech analyst at Needham & Co., named some biotech stocks that look attractive.
Shares of Lilly are off about 6% over the past month – down much more than the overall healthcare sector. Why can’t Lilly get any love?
Medtronic spokesman Steve Cragle sent CNBC this clarification to Mr. Hawkins' answer to Mike Huckman's question regarding the Senate investigation into a doctor who has done consulting work for MDT.
The judge threw the book at the man, but at the same time he didn't sentence him by the book. Andrew Bodnar pleaded guilty to his role in the generic Plavix brouhaha a couple of years ago. And yesterday a District Court judge fined him $5,000 and ordered Bodnar to write a book about what happened. Write a book!
For people struggling with diabetes, the bathroom scale can be the enemy. But new developments may change that and more!
"It's a risky business." I don't think I'll ever forget when a Chief Financial Officer said that at an investor conference last year in lieu of reading the whole boring boilerplate "Safe Harbor Statement."
In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer.
A year or so ago, when customers buttonholed the pharmacists at Almand’s Drug Store here the questions were invariably about dosing or side effects. These days, they are almost always about cost.
Wall Street is terrified of both inflation and deflation, high and low oil prices, a strong and a weak dollar. Here’s how you avoid the panic.
The cost of drugs was a hot topic at ASCO this year, especially with the release of the big test results combining two very expensive treatments for lung cancer. The study showed using Avastin from Roche and Genentech and a pill, Tarceva, from OSI Pharmaceuticals, Roche and Genentech slowed down progression of the disease by a little more than a month.
I'm happy to report that I'm scribbling out this blog from the air-conditioned comfort of the convention center in Orlando. It's the first time in my six or seven years of covering ASCO that the organization has let CNBC broadcast live from inside. And, guess what? No one seems freaked out about it.
How will male General Motors retirees get their motor runnin'? Do they start paying for their impotence drugs out of their own pocket? Because apparently, under the new deal the company won't pick up the tab anymore.
Plus, Cramer makes the call on insurance, the autos, natural gas and more.
Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.
I'm juggling the Amylin Pharmaceuticals proxy fight, then ASCO (American Society of Clinical Oncology), then the Biogen Idec shareholder meeting and then the ADA (American Diabetes Association) meeting all within a week-and-a-half.
Cramer tries to explain why the stock is down in Wednesday trading. Plus, calls on retail, solar energy, a new Dow component and more.
Plus, Cramer explains why First Niagara is just the type of bank that investors want right now.